论文信息 - Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients - 字舞流文

Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients

Yuxuan Song | Songchen Han | Tao Xu

[1] Dun-Chang Mo,et al. Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis , 2023, World Journal of Urology.

[2] D. Cella,et al. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment , 2023, Nature Reviews Urology.

[3] M. Atkins,et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. , 2022, European urology.

[4] Gail M. Williams,et al. Advances in the meta-analysis of heterogeneous clinical trials I: The inverse variance heterogeneity model. , 2015, Contemporary clinical trials.

[5] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[6] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .